Paclitaxel, ifosfamide, cisplatin (TIP) for the treatment of intermediateand poor-risk nonseminomatous germ cell tumors with an inadequate decrease in tumor markers: a phase II study

E. R. Israelyan; A. A. Tryakin; A. A. Rumyantsev; M. Yu. Fedyanin; A. S. Tyulyandina; S. A. Protsenko; A. A. Paichadze; Yu. M. Bychkov; G. S. Yunaev; S. A. Tyulyandin

Malignant tumours
Zlokačestvennye opuholi

ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)

User

eng | рус

Malignant tumours

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Israelyan E.R., Tryakin A.A., Rumyantsev A.A., Fedyanin M.Yu., Tyulyandina A.S., Protsenko S.A., Paichadze A.A., Bychkov Yu.M., Yunaev G.S., Tyulyandin S.A. Paclitaxel, ifosfamide, cisplatin (TIP) for the treatment of intermediateand poor-risk nonseminomatous germ cell tumors with an inadequate decrease in tumor markers: a phase II study. Malignant tumours. 2022;12(3):11-20. (In Russ.) https://doi.org/10.18027/2224-5057-2022-12-3

Views PDF (Rus): 344

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles

Editor-in-Chief

Nosov D.A.

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

E. R. Israelyan
Pirogov Russian National Research Medical University; N. N. Blokhin National Medical Research Center of Oncology
Russian Federation

Edgar R. Israelyan, clinical resident of Department Of Oncology; clinical resident Oncology Department of Drug Therapy (Chemotherapy) No. 4

Moscow

A. A. Tryakin
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation

Alexey A. Tryakin, MD, PhD, DSc, Deputy Director for Research, Head of Medical Oncology (Chemotherapy) Department No. 2

Moscow

A. A. Rumyantsev
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation

Aleksey A. Rumyantsev, MD, PhD, Oncologist, Oncology Department of Drug Therapy (Chemotherapy) No. 4

Moscow

M. Yu. Fedyanin
N. N. Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center «Kommunarka»
Russian Federation

Mikhail Yu. Fedyanin, MD, PhD, DSc, Senior Researcher, Oncology Department of Drug Therapy (Chemotherapy) No. 2; Head, Chemotherapy Service; Scientific Advisor, National Medical and Surgical Center named after N. I. Pirogov

Moscow

A. S. Tyulyandina
N. N. Blokhin National Medical Research Center of Oncology; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Alexandra S. Tyulyandina, MD, PhD, DSc, Head of Medical Oncology (Chemotherapy) Department No. 4; Professor, Department of Oncology, N. V. Sklifosovsky Institute of Clinical Medicine

Moscow

S. A. Protsenko
N. N. Petrov Research Institute of Oncology
Russian Federation

Svetlana A. Protsenko, MD, PhD, DSc, Head of the Chemotherapy and Innovative Technologies Department

St. Petersburg

A. A. Paichadze
National Medical Research Radiological Centre
Russian Federation

Anna A. Paichadze, MD, PhD, Oncologist, Oncology Department of Drug Therapy (Chemotherapy)

Moscow

Yu. M. Bychkov
Russian Scientific Center of Roentgenoradiology
Russian Federation

Yury M. Bychkov, MD, PhD, Head of Oncology Day Patient Department

Moscow

G. S. Yunaev
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation

Grigory S. Yunaev, Anesthesiologist-Intensivist, Head of the Rehabilitation and Intensive Care Department

Moscow

S. A. Tyulyandin
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation

Sergey A. Tyulyandin, MD, PhD, DSc, Professor, Honored Scientist of the Russian Federation, Chief Researcher

Moscow

Notifications

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Malignant tumours

For citations:

Cookies policy